An Open Label Study of Oral Enzastaurin in Participants With Cancer

Summary

This study will collect further basic safety data on participants with cancer treated with enzastaurin. This study is not open to the public. The purpose of the this study is to extend the clinical experience of participants who complete enzastaurin therapy per clinical pharmacology and biopharmaceutics studies conducted by Eli Lilly and Company and who may benefit from continued enzastaurin therapy.

Timeline

Start

2006-03

Primary completion

2009-07

Completion

2009-07

Drugs

Indications